Product information and disease descriptionProduct descriptionProduct informationDosing and administration
Dosage
4 evidence topics · 5 sources
Randomized dose and open-label extension dose
Dose selection for the RINGSIDE phase III trial
Dose reduction levels and time to first dose modification
“Median Time to First Dose Reduction” (opens the source at this quote in a new tab)
“to 0.9 mg (n=60): 3.7 (IQR 1.8, 8.3) months” (opens the source at this quote in a new tab)
“to 0.6 mg (n=36): 7.3 (IQR 3.0, 12.5) months” (opens the source at this quote in a new tab)
“Median Time to First Dose Interruption” (opens the source at this quote in a new tab)
“Varegacestat (n=63): 2.5 (IQR 1.0, 5.7) months” (opens the source at this quote in a new tab)
“Dose Reduction” (opens the source at this quote in a new tab)
“Varegacestat 80% | Placebo 9%” (opens the source at this quote in a new tab)
“Dose Interruption” (opens the source at this quote in a new tab)
“Varegacestat 65% | Placebo 14%” (opens the source at this quote in a new tab)
Dose levels and dose modification rules for BMS-986115
“BMS-986115 was administered orally once daily (QD) at doses of 0.3, 0.6, 1.2, 1.5, and 2 mg (Arm A) or twice weekly (BIW) on consecutive days at doses of 2, 4, 8 mg (Arm B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dose interruption (up to 28 days) and/or dose modification (up to 2 dose reductions) were permitted in the event of study drug toxicity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote